Under construction – not a live service
Sign in

2026-525543-32-00RecruitingPhase 1

A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 May 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
10 (estimated)
First submitted
13 Mar 2026
Start date
17 Jun 2026
Lead sponsor
Oncopeptides AB
Diseases
Glioblastoma
EU CT number
2026-525543-32-00

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 10
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a glioblastoma that has come back and who are already scheduled for surgery. It studies how a single dose of melflufen reaches the tumour tissue.

Age
18 years or older
Sex
All sexes can join
Disease stage
Recurrent (returning) glioblastoma, with surgery already planned

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Oslo Universitetssykehus HFOsloNorwayRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.